Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2025)

Historic Operating Leases for Protalix BioTherapeutics (PLX) over the last 7 years, with Q3 2025 value amounting to $6.8 million.

  • Protalix BioTherapeutics' Operating Leases rose 6235.63% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 6235.63%. This contributed to the annual value of $4.0 million for FY2024, which is 1287.6% down from last year.
  • Protalix BioTherapeutics' Operating Leases amounted to $6.8 million in Q3 2025, which was up 6235.63% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Operating Leases registered a high of $6.8 million during Q3 2025, and its lowest value of $3.8 million during Q1 2025.
  • Its 5-year average for Operating Leases is $4.4 million, with a median of $4.3 million in 2024.
  • Over the last 5 years, Protalix BioTherapeutics' Operating Leases had its largest YoY gain of 6235.63% in 2025, and its largest YoY loss of 1529.23% in 2025.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Operating Leases stood at $4.4 million in 2021, then dropped by 4.73% to $4.2 million in 2022, then rose by 10.84% to $4.6 million in 2023, then dropped by 12.88% to $4.0 million in 2024, then soared by 68.41% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $3.9 million for Q2 2025, and $3.8 million during Q1 2025.